I had a few errands to run today, which has delayed me from having a look at the tape. On the surface, it looks like more of the same: risk on. Solar stocks are up again, led by FSLR, JASO, JKS and LDK. It’s only a matter of time before SCTY and EMKR explode to the upside. That mini-CREE, RVLT, is up huge, as many have expected. The market has become somewhat predictable in the sense that everything goes up, eventually.
The one stock that I’ve highlighted inside of The PPT but have never purchased due to exchange listing is ONVO. They want to ‘print’ livers. I kid you not. Fascinating stuff, go check it out.
It looks like TXTR and YELP are coming in. I am a buyer of both names into any moderate pullback.
I’m up about 0.6% right now, clamoring for IMMR to get going–fully content with GS spinning higher.
If you enjoy the content at iBankCoin, please follow us on Twitter
If you aren’t on board OA ..is going insane HOT on his picks
he’s great.
bought NDLS last week, does anyone have a thought on it? thanks
also JASO to the moon. its a rock star
love NDLS
ONVO is the real deal, spec buying now before NYSE MKT listing but, 3D printing of living tissue and the growth of a new liver is not biotech-it is bio revolution. Buy at your peril, ignore and you die.
My favorite long term idea.
Fly, are you still waiting patiently for WETF? It keeps trickling up, but I’m watching the rest of my portfolio move. It’s boring me!
I am long WETF. I am keeping it for a while.
ONVO flew upon uplisting since it is a hot theme biotech involved with a revolutionary development (3D). Another hot theme biotech poised to make a similar-magnitude run upon uplisting is NVIV, who have created a biopolymer implant for acute spinal injury, and have been approved to use this as a Human Used Device exemption in patient trials at Boston and Philadelphia hospitals. And yes, three African green monkey studies actually proved they could make monkeys walk, run, and climb ladders again using both legs a couple months after half the spinal cord was severed. NVIV will pop 60% upon uplisting and may double upon startup of these trials in September.